GENE ONLINE|News &
Opinion
Blog

2022-01-10| Asia-PacificIPO

Vertex Is Looking to Become Singapore’s First SPAC

by Joy Lin
Share To

Last September, the Singapore Exchange (SGX) changed its framework to allow special purpose acquisition companies (SPACs) to list. Now, Vertex Technology Acquisition Company (VTAC) is set to become the first SPAC to list in the country, after the company lodged a preliminary prospectus with the Monetary Authority of Singapore (MAS).

A subsidiary of Singapore venture capital firm Vertex Holdings, VTAC is seeking to raise S$200 million (nearly $150 million), by selling 40 million units at an offered price of S$5.00 each.  

VTAC announced that 13 cornerstone investors, including UBS Asset Management, Venezio Investments, and Fullerton Fund Management Company, have subscribed to 65% of the shares offered, accounting for 22.2 million units that will raise S$111 million. 

Its sponsor Vertex Venture Holdings have also booked $30 million for the fundraising through its subsidiary Vertex Co-Investment Fund. 

When it lists at the end of the month, VTAC will have 24 months to complete a reverse merger. While VTAC did not disclose any specific combination targets in its prospectus, its focus will be on biotech and digital healthcare, and technologies related to artificial intelligence, cyber security and enterprise, consumer Internet, finance, autonomous driving, and new energy vehicles.

SPACs in Asia 

 

SPAC listings may become more common in Asia as countries change their frameworks. Hong Kong recently changed its rules to allow SPACs to begin listing this January. Elsewhere, SPACs have already been greenlighted in Korea and Malaysia, and are given 36 months to complete an acquisition compared to the usual 24.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
AbbVie Boosts Global Manufacturing with $223 Million Expansion in Singapore
2024-01-29
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
LATEST
AI’s Promise to Profits: How IBM is Maximizing Business ROI with Accelerated Computing
2025-03-19
Edge Computing: The Next Big Thing in AI and Automation
2025-03-19
Neurosurgery Now: NVIDIA’s Holoscan AI Brings Real-Time 3D Vision to Enhance Surgical Precision at 2025 GTC
2025-03-18
NVIDIA GTC 2025: BioMap’s xTrimo — The AI Model That’s Changing Biotech and Drug Discovery
2025-03-18
AstraZeneca Acquires Cell Therapy Company in $1 Billion Deal to Develop In Vivo Cancer Treatments
2025-03-18
Gene Therapy Achieves Complete Cure for Sickle Cell Anemia in New York Patient
2025-03-17
NICE Recommends New Endometriosis Treatment for NHS Patients
2025-03-14
EVENT
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
Scroll to Top